Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) FCF Margin (2016 - 2025)

Spero Therapeutics' FCF Margin history spans 10 years, with the latest figure at 17.76% for Q4 2025.

  • For Q4 2025, FCF Margin rose 4498416.0% year-over-year to 17.76%; the TTM value through Dec 2025 reached 18.0%, up 8027.0%, while the annual FY2025 figure was 26.84%, 629230.0% up from the prior year.
  • FCF Margin reached 17.76% in Q4 2025 per SPRO's latest filing, down from 320.14% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 4241.43% in Q1 2024 to a low of 45001.92% in Q4 2024.
  • Average FCF Margin over 5 years is 2858.33%, with a median of 109.02% recorded in 2025.
  • Peak YoY movement for FCF Margin: skyrocketed 4805844bps in 2021, then plummeted -4497768bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 219.5% in 2021, then grew by 21bps to 265.17% in 2022, then tumbled by -109bps to 24.25% in 2023, then plummeted by -185500bps to 45001.92% in 2024, then skyrocketed by 100bps to 17.76% in 2025.
  • Per Business Quant, the three most recent readings for SPRO's FCF Margin are 17.76% (Q4 2025), 320.14% (Q3 2025), and 149.92% (Q2 2025).